Portal fibroblasts: A renewable source of liver myofibroblasts
Steven P. O’Hara, Nicholas F. LaRusso – 15 April 2022
Prophylactic embolization of large spontaneous portosystemic shunts with transjugular intrahepatic portosystemic shunt (TIPS): A panacea for post‐TIPS hepatic encephalopathy?
Dhiraj Tripathi, Christophe Bureau – 15 April 2022
Reply
Alexander S. Vogel, Gene Y. Im – 15 April 2022
Coronavirus disease 2019 (COVID‐19) vaccination in patients with cirrhosis: Does it work?
Alberto Calleri, Margherita Saracco, Renato Romagnoli, Silvia Martini – 15 April 2022
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis
Cornelius Engelmann, Niklas F. Aehling, Stefan Schob, Ines Nonnenmacher, Luise Handmann, Jane Macnaughtan, Adam Herber, Alexey Surov, Thorsten Kaiser, Timm Denecke, Rajiv Jalan, Daniel Seehofer, Michael Moche, Thomas Berg – 13 April 2022 – Cachexia occurs in late stages of liver cirrhosis, and a low‐fat mass is potentially associated with poor outcome. This study compared different computed tomography (CT)–derived fat parameters with respect to its prognostic impact on the development of complications and death before and after liver transplantation.
Outcomes of liver transplantation in recipients with previous coronavirus disease 2019 infection
Akila Rajakumar, Susan Paulin, Premchandar Velusamy, Vidya Devarajan, Dinesh Jothimani, Rajesh Rajalingam, Ashwin Rammohan, Mohamed Rela – 13 April 2022
The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents
Donald M. Jensen, Allison Rzepczynski, Emily E. Jensen, Nancy Reau – 12 April 2022
We need a new approach to clinical trials in alcohol‐associated hepatitis: Is there a lesson in RECOVERY?
Michael Ronan Lucey, Mark R. Thursz – 12 April 2022
Reply
Paul H. Hayashi, M. Isabel Lucena – 12 April 2022
Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV
Maurice Michel, Christian Labenz, Malena Anders, Alisha Wahl, Lisann Girolstein, Leonard Kaps, Wolfgang M. Kremer, Yvonne Huber, Peter R. Galle, Martin Sprinzl, Jörn M. Schattenberg – 11 April 2022 – Hepatic steatosis (HS) related to nonalcoholic fatty liver disease (NAFLD) is increasing globally. In people living with human immunodeficiency virus (PLWH) risk factors of HS are increased. The impact of HS on outcomes and in particular health‐related quality of life (HRQL) in PLWH remains unknown.